ESTRO 2025 - Abstract Book

S1435

Clinical - Lung

ESTRO 2025

After a median follow-up of 15.5 months (IQR 7.8 – 30.3 months), the median overall survival (OS) was 73.8 months (95% CI: 33.5-NA) (Figure1). During the follow-up period, a total of 14 events (deaths) were observed. Seventeen patients experienced local failure. The median local control (LC) was 23.5 months (95% CI: 15.3-39.9). The median PFS was estimated at 15.7 months (95% CI: 8.6-39.2), indicating that 50% of the patients experienced disease progression before one year and half. We observed no grade 4-5 toxicities. The only grade 3 toxicity was pneumonitis requiring hospitalization in one patient. Eight patients experienced grade 2 dyspnea, two patients reported grade 2 thoracic pain, two had rib fractures, and one patient had grade 2 esophagitis.